The role of IL-6 in tumor immunity and related research progress
Cellular Signalling · 2026-07 · 143 · 112460
DOI: 10.1016/j.cellsig.2026.112460 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cellular Signalling, 2026-07. Verfasst von Ping Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China. Hauptthemen laut MEDLINE: Interleukin-6, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: Zhejiang Province Basic Public Welfare Research Program, Zhejiang Province Natural Science Foundation.
Abstract (Originalsprache)
IL-6 is the primary mediator of inflammation. It can be secreted by immune cells, tumor cells, and stromal cells, which is highly expressed in tissues from tumors. Through its downstream signaling pathway, IL-6 regulates nearly every aspect of the tumor to encourage its occurrence and progression. Additionally, it impacts immunosuppressive molecule expression, impacts the tumor microenvironment's immunological and non-immune cell counts and composition, and promotes the growth of a tumor microenvironment that suppresses the immune system. Immunotherapy is a commonly used treatment method nowadays. However, in most patients with cancer, immunotherapy often exhibits low response rates and drug resistance. The secret to increasing the efficacy of tumor immunotherapy is to overcome the tumor microenvironment's immunosuppressive state. In recent years, researchers have developed a number of drugs that target the IL-6/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling cascade, and related studies on combining immune checkpoint inhibitors with it, providing the new direction for immunotherapy in tumor patients. This article reviews the specific mechanism of IL-6 on tumor immunity and summarizes the latest research findings on blocking IL-6 or its downstream-related signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China.
- Department of Medical Oncology, Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an 223002, China.
- Department of Biomedical Engineering, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China.
- Department of Medical Oncology, Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an 223002, China. Electronic address: ha2280@126.com.
- Department of General Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China. Electronic address: 8012023@zju.edu.cn.
Förderung
- Zhejiang Province Basic Public Welfare Research Program
- Zhejiang Province Natural Science Foundation
Zitieren
APA
Huang, P., Yin, R., Xu, W., Wang, S., Yong, H., & Yang, T. (2026). The role of IL-6 in tumor immunity and related research progress. Cellular Signalling, 143, 112460. https://doi.org/10.1016/j.cellsig.2026.112460
Vancouver
Huang P, Yin R, Xu W, Wang S, Yong H, Yang T. The role of IL-6 in tumor immunity and related research progress. Cellular Signalling. 2026;143:112460. doi:10.1016/j.cellsig.2026.112460
BibTeX
@article{Huang2026,
author = {Huang, Ping and Yin, Rong and Xu, Weina and Wang, Shenggeng and Yong, Hongmei and Yang, Tian},
title = {The role of IL-6 in tumor immunity and related research progress},
journal = {Cellular Signalling},
year = {2026},
volume = {143},
pages = {112460},
doi = {10.1016/j.cellsig.2026.112460}
}
EUVIMED